CRAN

This hurricane season, Verizon readies the fleet

Retrieved on: 
Wednesday, May 24, 2023
CRAN, BAT, COLT, Big Mac, Emergency, WOLF, Atmosphere, Tether, SPOT, HAWK, Wireless router, THOR, MEC, Cyclone, STUD, ENB, Wi-Fi, GOAT, Repeated sequence (DNA), WECC, Military personnel, MEOW, Risk, CROW, Emergency operations center, MCT, Cell, Hurricane season, Lifting, Radio, Mobile asset management, Verizon Communications, Weather, SOW, NOW, Lightweight, SNOW, PIG, LTE, Video, Electric battery, Communications satellite, Satellite navigation device, Mobile telephony, Mobile phone, Intermodal freight transport, Heavy equipment, Trailer

One hundred percent of Verizon macro cell sites which provide large area coverage have backup battery power and 79% have backup generators.

Key Points: 
  • One hundred percent of Verizon macro cell sites which provide large area coverage have backup battery power and 79% have backup generators.
  • In case emergency network recovery becomes necessary after a hurricane makes landfall, Verizon is prepared to respond quickly.
  • Additionally, Verizon boasts an industry-leading 200 satellite-based portable network assets.
  • Verizon Frontline Crisis Response Team members set up portable cell sites, WiFi hotspots, free charging stations and other Verizon Frontline devices and solutions that help enable mission-critical communication and/or boost network performance.

Release of Olink® Analyze 3.1 streamlines proteomic analysis to connect data to biological insight

Retrieved on: 
Tuesday, June 28, 2022
GLOBE, Biomarker, Comprehensive, Statistics, CRAN, Data visualization, Analyse, Protein, Quality control, Data science, Data analysis, Collection, Medical device

Olink Analyze is an R software package, a collection of functions written in R programming language, created to streamline the analysis of Olink data.

Key Points: 
  • Olink Analyze is an R software package, a collection of functions written in R programming language, created to streamline the analysis of Olink data.
  • Olink Analyze enables users to easily extract biological insight from Olink data using built-in statistical analysis and visualization functions and expedites the data analysis process with quality control visualizations and easy integration with other R packages.
  • Olink Analyze functions also help with data pre-processing, quality control and exploratory data analysis, statistical analysis, and data visualization.
  • With Olink Analyze we provide our customers a highly versatile toolbox to make data analysis easier and facilitate extracting biological insights from Olink data.

WPD Pharmaceuticals Signs Consortium Agreement on EuroNanoMed Project

Retrieved on: 
Monday, March 7, 2022
Recurrence, Patient, Consortium, Research, Complementarity, Radiation therapy, Hospital, FSE, Prognosis, Biotechnology, WPD, University, NPS, CSE, CRAN, Efficiency, The Consortium Agreement of 1954, Nanoparticle, Glioblastoma, GBM, Brain, Institute, Information science, NH, Neoplasm, Cell, European Innovation Council, Oslo University Hospital, Wake Forest University, Jagiellonian University, Automation, Radiation, CNRS, University of Lorraine, Virology, National Scientific and Technical Research Council, Tissue, GLOBE, Research institute, Pharmaceutical industry, Medical imaging, Nanomedicine

VANCOUVER, British Columbia, March 07, 2022 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the Company or WPD) a clinical-stage pharmaceutical company, is excited to announce that it has received the final version of the signed Consortium Agreement related to the EuroNanoMed Project.

Key Points: 
  • VANCOUVER, British Columbia, March 07, 2022 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the Company or WPD) a clinical-stage pharmaceutical company, is excited to announce that it has received the final version of the signed Consortium Agreement related to the EuroNanoMed Project.
  • Over the three-year project timeline, the consortium aims to plan and adapt the X-ray doses given to the patient to maximize radiotherapy efficiency on these high-grade tumors while preserving the adjacent healthy tissue.
  • This project will base its work on pre-clinical experiments at different biological scales (cells, tissues, and in vivo on rodent models) and algorithms' development.
  • The sublicense territory from CNS Pharmaceuticals and Moleculin Biotech includes about 29 countries in Europe and Asia, including Russia, depending on the compound.